Invagen Pharmaceuticals, Inc.

Invagen Pharmaceuticals, Inc. (United States) has no DMF, CEP or site registration linked in our records. 48 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Invagen Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/invagen-pharmaceuticals-inc

Overview

Invagen Pharmaceuticals, Inc. is a leading pharmaceutical company that focuses on the development, manufacture, and distribution of generic medicines. As a subsidiary of the global pharmaceutical company Cipla Limited, Invagen is committed to providing affordable healthcare solutions worldwide.

Core services & business areas

Contract ManufacturingRegulatory AffairsQuality Control

Therapeutic areas

FDA compliance signals

48 FDA enforcement records linked to this company.

  • recall — Class I2024-01-17

    Defective Container: powder may leak out of the pouch

  • recall — Class III2020-05-27

    Failed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing.

  • 4832019-12-06

    Testing and release for distribution

  • 4832019-12-06

    Written in-process control procedures

  • 4832019-12-06

    Batch production and Batch Control Record Requirements

  • recall — Class III2019-07-10

    Defective Container; actuator may improperly function and affect dose delivery.

  • recall — Class II2019-04-24

    Presence of Particulate Matter.

  • recall — Class II2019-04-24

    Presence of Particulate Matter.

  • recall — Class II2019-04-24

    Presence of Particulate Matter.

  • recall — Class III2018-10-17

    Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.

  • recall — Class III2018-09-26

    Failed impurities/ degradation specifications: Out-of-specification results were observed in the meta-chlorobenzoic acid impurity in batches 18 months or older from date of manufacture in the 90 count bottle size.

  • 4832018-05-25

    Scientifically sound laboratory controls

  • 4832018-05-25

    Failure to meet specifications

  • 4832018-05-25

    Mix-up

  • 4832018-05-25

    Investigations of discrepancies, failures

  • 4832018-05-25

    Backup file not maintained

  • 4832018-05-25

    Written program not followed

  • recall — Class III2018-04-18

    Failed impurities/degradation specifications: Failure to water content and impurity

  • recall — Class III2018-04-11

    Failed Dissolution Specifications; during stability testing

  • recall — Class III2018-04-11

    Failed Dissolution Specifications; during stability testing

  • 4832015-05-26

    Procedures not in writing, fully followed

  • 4832013-03-08

    Control procedures to monitor and validate performance

  • 4832013-03-08

    Procedures not in writing, fully followed

  • 4832013-03-08

    Valid stability test methods

  • 4832012-06-14

    Handling and Storage to Prevent Contamination

  • 4832012-03-02

    Procedures for non-sterile drug products

  • 4832012-03-02

    Investigations of discrepancies, failures

  • 4832011-04-13

    Written procedures not established/followed

  • 4832011-04-13

    Scientifically sound laboratory controls

  • 4832011-04-13

    Procedures not in writing, fully followed

  • 4832011-04-13

    Returned drug procedures in writing and followed

  • 4832010-11-10

    Sampling and testing plans not described

  • 4832010-11-10

    Complete instructions, procedures, specifications et. al.

  • 4832010-11-10

    Reprocessing procedures not written or followed

  • 4832010-11-10

    Failure to meet specifications

  • 4832010-11-10

    Complaint Handling Procedure

  • 4832010-11-10

    Procedures not in writing, fully followed

  • 4832010-11-10

    Procedures To Be in Writing

  • 4832010-11-10

    In-process samples representative, identified properly

  • 4832010-08-27

    Procedures not in writing, fully followed

  • 4832010-08-27

    Written record of investigation incomplete

  • 4832010-08-27

    Failure to meet specifications

  • 4832009-05-12

    Written procedures not established/followed

  • 4832009-05-12

    Procedures To Be in Writing

  • 4832009-05-12

    SOPs not followed / documented

  • 4832009-05-12

    Non-applicant reports directly to FDA

  • 4832009-05-12

    Incomplete periodic safety report

  • 4832009-05-12

    Wrong form - domestic ADE

For suppliers

Is this Invagen Pharmaceuticals, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.